Phase I/II study of oncolytic HSVGM-CSFin combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck

Clinical Cancer Research

Volumn 16, Issue 15, 2010, Pages 4005-4015

  Harrington, Kevin J ^a,b   Hingorani, Mohan ^b   Tanay, Mary Anne ^b   Hickey, Jennifer ^b   Bhide, Shreerang A ^b   Clarke, Peter M ^b   Renouf, Louise C ^b   Thway, Khin ^a,b   Sibtain, Amen ^c   McNeish, Iain A ^c,d   Newbold, Kate L ^b   Goldsweig, Howard ^e   Coffin, Robert ^e   Nutting, Christopher M ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e Biovex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC HERPES VIRUS; ONCOVEX GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COUGHING; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPHAGIA; DYSPHORIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; HUMAN TISSUE; HYPOGEUSIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INJECTION SITE BLEEDING; INJECTION SITE REACTION; INSOMNIA; KIDNEY FAILURE; LEUKOPENIA; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTOPENIA; MALAISE; MALE; MOUTH ULCER; NAUSEA; NECK DISSECTION; NEUTROPENIA; ODYNOPHAGIA; PATIENT MONITORING; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SERODIAGNOSIS; SIDE EFFECT; SOLID TUMOR; SORE THROAT; SQUAMOUS CELL CARCINOMA; STOMACH DISCOMFORT; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; THRUSH; TINNITUS; TREATMENT RESPONSE; UREMIA; VIRUS REPLICATION; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; ONCOLYTIC VIROTHERAPY; RADIOTHERAPY; SIMPLEXVIRUS; TREATMENT OUTCOME;

EID: 77955104827     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0196     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Skaria S, Powell C, Bhide S, Newbold K, Nutting CM, Harrington KJ. Optimisation of radiotherapy for squamous cell cancer of the head and neck. Otorhinolaryngologist 2007;2:35-46.
3. Bernier J. A multidisciplinary approach to squamous cell carcinoma of the head and neck: an update. Curr Opin Oncol 2008;20: 249-55. (Pubitemid 351507543)
4. Lavertu P, Adelstein DJ, Saxton JP, et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck 1997;19: 559-66.
5. Brizel D, Albers M, Fisher S, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804.
6. Stenson KM, Haraf DJ, Pelzer H, et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg 2000;126:950-6. (Pubitemid 30658293)
7. McHam SA, Adelstein DJ, Rybicki LA, et al. Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? Head Neck 2003;25:791-8.
8. Frank DK, Hu KS, Culliney BE, et al. Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer. Laryngoscope 2005;115:1015-20.
9. Stenson KM, Huo D, Blair E, et al. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope 2006;116:33-6.
10. Goguen L, Posner MR, Tishler R, et al. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132: 526-31.
11. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow-up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33: 210-22.
12. Adelstein D, Li Y, Adams G, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
13. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22: 69-76.
14. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18: 1458-64. (Pubitemid 30205391)
15. Bonner J, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78.
16. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10:292-303.
17. Simpson GR, Coffin RS. Oncolytic herpes simplex viruses. In: Harrington KJ, Vile RG, Pandha HS, editors. Viral therapy of cancer. Chichester (UK): John Wiley and Sons, Ltd.; 2008, p. 115-38.
18. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737-47.
19. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71.
20. Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther 2008;10:362-70.
21. Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010;21:91-8.
22. Guerrero Urbano T, Clark CH, Hansen VN, et al. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol 2007;85:36-41.
23. Psyrri A, Gouveris P, Vermorken JB. Human papillomavirus-related head and neck tumors: clinical and research implication. Curr Opin Oncol 2009;21:201-5.